Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bingham, S.
Right arrow Articles by Emery, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bingham, S.
Right arrow Articles by Emery, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 2-5
© 2000 British Society for Rheumatology

Editorials

Resistant rheumatoid arthritis clinics— a necessary development?

S. Bingham and P. Emery

Rheumatology and Rehabilitation Research Unit, University of Leeds, 36 Clarendon Road, Leeds LS2 9NZ, UK

Rheumatologists have always been aware of the limitations of the therapy available to them. For many years the drugs used on patients with rheumatoid arthritis (RA) produced such a high withdrawal rate due to both toxicity and the lack of efficacy that there was some doubt whether they had any impact on the underlying disease at all. With better study design and more efficient use of drugs it is now clear that disease-modifying anti-rheumatic drugs (DMARDs) do alter the disease course as evidenced by retardation of bony erosions and improvement in function [1]. However, conventional therapy has many well-recognized toxicities and is still incompletely effective, with few patients entering remission. A major change in prescribing in rheumatology is about to occur with the licensing of several new drugs including the pyrimidine synthesis inhibitor leflunomide (Arava) and two tumour necrosis factor (TNF) blocking agents etanacept (Enbrel) and infliximab (Remicade). . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Gause
Progress in the treatment of rheumatic disease
Nephrol. Dial. Transplant., January 1, 2003; 18(1): 13 - 16.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. A. Quinn, P. G. Conaghan, and P. Emery
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?
Rheumatology, November 1, 2001; 40(11): 1211 - 1220.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. Porter, S. Bingham, and P. Emery
Re: Bingham and Emery. Resistant rheumatoid arthritis clinics--a necessary development?
Rheumatology, October 1, 2000; 39(10): 1154 - 1155.
[Full Text] [PDF]